Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis
نویسندگان
چکیده
Method 4022 patients (>=12 years old) were randomized into 4, 14-day double-blind, placebo-controlled SAR trials to receive MP29-02*, AZE, FP or placebo nasal sprays (all given as 1 spray/nostril bid). 612 patients (>=12 years old) were randomized into a 1-year, open-label, active-controlled, parallel-group chronic rhinitis trial to receive MP29-02* (1 spray/nostril bid) or FP nasal spray (2 sprays/nostril qd). For all studies the total daily dose of AZE and FP was 548 g and 200 μg respectively. Safety was assessed by incidence, type, and severity of adverse events, vital signs and nasal examination.
منابع مشابه
The journey from unmet need in allergic rhinitis to rationale for, and clinical development of, a new treatment option, MP29-02
• Currently considered first-line allergic rhinitis (AR) therapy provides insufficient symptom relief for many AR patients. • MP29-02 (Dymista®, Meda AB, Solna, Sweden) is a new intranasal AR therapy, consisting of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in a novel and patented formulation and advanced device. • It is indicated for the symptomatic relief of moderate/sever...
متن کاملA new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis.
BACKGROUND AND OBJECTIVE MP29-02 (Dymista), a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP), is significantly better than first-line therapy for the treatment of moderate-to-severe seasonal allergic rhinitis (SAR), and is well tolerated following 52 weeks of continuous use in chronic rhinitis. The aim of this study was to evaluate the long-term e...
متن کاملEscaping the trap of allergic rhinitis
Rhinitis is often the first symptom of allergy but is frequently ignored and classified as a nuisance condition. Ironically it has the greatest socioeconomic burden worldwide caused by its impact on work and on daily life. However, patients appear reticent to seek professional advice, visiting their doctor only when symptoms become 'intolerable' and often when their usual therapy proves ineffec...
متن کاملA new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.
Background Moderate-to-severe allergic rhinitis (AR) is often poorly controlled. Patients remain symptomatic on treatment, despite multiple therapies. A more effective treatment is needed. We assessed the efficacy of MP29-02* (a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in an advanced delivery system) during different seasons and for differen...
متن کاملMP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
Background Four previously published trials assessed the efficacy of MP29-02* (a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in an advanced delivery system) in seasonal allergic rhinitis (SAR) [1,2]. The first study compared MP29-02* to marketed AZE and FP [2]. The others compared MP29-02* to AZE and FP in the MP29-02* vehicle and delivery devi...
متن کامل